Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Autor: Coles, Alasdair J., Jones, Joanne L., Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D., Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf, Universitat Autònoma de Barcelona

Publikováno v: Coles, Alasdair J; Jones, Joanne L; Vermersch, Patrick; Traboulsee, Anthony; Bass, Ann D; Boster, Aaron; Chan, Andrew; Comi, Giancarlo; Fernández, Óscar; Giovannoni, Gavin; Kubala Havrdova, Eva; LaGanke, Christopher; Montalban, Xavier; Oreja-Guevara, Celia; Piehl, Fredrik; Wiendl, Heinz; Ziemssen, Tjalf (2022). Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple sclerosis journal, 28(5), pp. 842-846. Sage 10.1177/13524585211061335
Scientia

Funder: Sanofi; FundRef: https://doi.org/10.13039/100004339
Funder: Bayer Healthcare Pharmaceuticals
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac94721485f27958eef306cc37a3275
https://boris.unibe.ch/163565/1/Coles__2021__Autoimmunity_and_long-term_safety_alemtuzumab.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy of a Fourth Alemtuzumab Course in RRMS Patients from CARE-MS II Who Experienced Disease Activity After Three Prior Courses

Autor: Alroughani, Raed, Traboulsee, Anthony, Boster, Aaron, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard Al

Publikováno v: In Multiple Sclerosis and Related Disorders January 2020 37

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Autor: Steingo, Brian, Al Malik, Yaser, Bass, Ann D, Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G, Mitsikostas, Dimos D, Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D Alastair S, CAMMS223, CAMMS03409, and TOPAZ Investigators

Publikováno v: Journal of Neurology

Funder: Sanofi; doi: http://dx.doi.org/10.13039/100004339
Funder: Bayer Healthcare Pharmaceuticals
Background: In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous int

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e09533967d79260b9abb6c1323e340f
https://www.repository.cam.ac.uk/handle/1810/324347

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.

Autor: Coles, Alasdair J, Jones, Joanne L, Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D, Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf

Publikováno v: Multiple Sclerosis Journal; Apr2022, Vol. 28 Issue 5, p842-846, 5p